B-cell activating factor and A proliferation-inducing ligand in relation to intima-media thickness as biomarkers of premature atherosclerosis in systemic lupus erythematosus patients
Authors:
- 14 May 2022
- journal article
- research article
- Published by Elsevier in The American Journal of the Medical Sciences
- Vol. 364 (5) , 646-654
Abstract
No abstract availableKeywords
This publication has 49 references indexed in Scilit:
- Decreased serum level of IL-21 in new-onset systemic lupus erythematosus patientsRheumatology International, 2013
- Semiquantified Noncalcified Coronary Plaque in Systemic Lupus ErythematosusThe Journal of Rheumatology, 2012
- Mycophenolate mofetil but not atorvastatin attenuates atherosclerosis in lupus-prone LDLr−/− miceAnnals of the Rheumatic Diseases, 2012
- Increase in IL-21 producing T-cells in patients with systemic lupus erythematosusArthritis Research & Therapy, 2011
- Mycophenolate mofetil (MMF) does not slow the progression of subclinical atherosclerosis in SLE over 2 yearsRheumatology International, 2011
- Accelerated Atherosclerosis in Systemic Lupus Erythematosus: Role of Proinflammatory Cytokines and Therapeutic ApproachesJournal of Biomedicine and Biotechnology, 2010
- Crucial Role for BAFF-BAFF-R Signaling in the Survival and Maintenance of Mature B CellsPLOS ONE, 2009
- Raised serum APRIL levels in patients with systemic lupus erythematosusAnnals of the Rheumatic Diseases, 2005
- Inverse association between circulating APRIL levels and serological and clinical disease activity in patients with systemic lupus erythematosusAnnals of the Rheumatic Diseases, 2004
- Derivation of the sledai. A disease activity index for lupus patientsArthritis & Rheumatism, 1992